Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Benzoate and/or NAC in Early Schizophrenia Spectrum Disorder
NCT03510741Phase 2Completed
- Sponsor
- Pakistan Institute of Living and Learning
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium benzoate, acetylcysteine in schizophrenia, sponsored by Pakistan Institute of Living and Learning. Started Jan 2019; status: completed.
02
Drugs
sodium benzoateacetylcysteine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03510741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510741.